

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

Nerviano Medical Sciences announces new organizational structure and management team including key appointments

Nerviano, 5 May 2022 — Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancers, today announces the new organizational structure and key appointments of the new management team, effective immediately.

The new organizational structure is designed to:

- Reposition the company's new vision as a top-performing biotech company recognized globally by peers, patients and physicians,
- Implement an organizational structure that can truly ensure to discover novel ways to treat patients and smartly push the boundary in development to make our medicines available to patients around the globe
- Drive the successful delivery of the transformation plan and address the key strategic priorities
- Accelerate the organizational change and streamline the operating processes
- Dedicate the proper focus and resources to further enhance value of the assets

The new structure will be led by the new CEO – Dr. Hugues Dolgos, who is the CEO of NMS Group Spa and the Chairperson of NMS Srl. This will streamline further the decision-making progress and optimize the support from the holding. The new management team is a balanced mix of NMS Srl's internal experts and newly acquired talents. The key appointments are:

- Antonella Isacchi, Director of Biotechnology and Head of Global Alliances with 25+ years of R&D experience takes up a newly created role, Chief Scientific Officer, who will oversee the overall research strategy, manage the company's scientific, technological, and research operations and will drive external collaboration and represent the scientific interests of the company.
- Alessia Montagnoli, Head of Biology, with 20+ years of R&D experience is promoted to Global Head of Asset Leadership, leading a team with a special focus dedicated to the company's strong pipeline assets to capitalize their critical importance and strongly increase their value.
- Lisa Mahnke, a physician/scientist with 16 years of experience in immunology, virology and in oncology development of large and small molecules, has joined NMS Srl to assume the role of Chief Medical Officer (currently as a Consultant) providing support and guidance for NMS Srl's portfolio and overall strategic development of the company and fortify our fast-to-market strategy. Lisa will be working from Boston and leading the creation of NMS Srl's US entity where she will be the CMO.
- Guoxian (Gregory) Wu, after four years of bringing growth and inspiration to NMS Srl leading with his expertise and vast experience in drug discovery and project management as the CEO of NMS Srl, moves from NMS Srl to NMS Group Spa and relocates to the US. Continuing his

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

important contribution to NMS Group, Greg will have new missions to expand the Group's horizon as Head of Drug Conjugate Innovation, and to help speeding up the process of the Group's critical presence in the US.

Dr. Hugues Dolgos commented: "After working with the extremely experienced and talented team here in Nerviano for a few months, we realized that only with the clear vision and the structure that reflects a biotech company can NMS Srl truly operate at full speed and maximize its capability. This is only the first step of an ambitious transformation plan that we just kicked off to unlock NMS srl's full potential. It sets up the sound basis from which we will implement positive changes with the strategic priorities at an accelerated pace. We very much look forward to achieving sustainable and profitable growth also in an untapped territory with the new global management team!"

About Nerviano Medical Sciences

[Nerviano Medical Sciences](#) S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing). A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it